Global Community

Presco Plc Delivers Explosive Earnings Growth in H1 2025 – A High-Yield, High-Confidence Investment Case Presco Plc’s H1 2025 results reveal a remarkable earnings story driven by record revenue growth, margin expansion, and consistent operational strength. With a 125.8% surge in revenue and a 128.2% boost in net profit, Presco has firmly established itself as a top-tier performer in Nigeria’s agro-industrial sector.

The company has demonstrated exceptional earnings growth in H1 2025, backed by operational leverage, prudent cost control , and a healthy balance sheet. Despite agricultural seasonality and inflationary pressures, Okomu Oil's performance suggests continued upside potential in the near-to-medium term.

NGX Group Plc delivered a robust performance in H1 2025, posting profit after tax of ₦4.22 billion , representing a significant growth of 97% compared to ₦2.14 billion in H1 2024. This sharp rebound highlights the resilience of NGX’s diversified earnings streams and the strength of its capital market infrastructure business amidst recovering macroeconomic conditions.

Nestlé Nigeria Plc has staged a remarkable recovery in H1 2025, reversing the prior year’s losses with impressive revenue and profit growth. A combination of robust top-line performance, margin expansion, and efficient cost control drove a swing from a ₦252.5 billion pre-tax loss in H1 2024 to an ₦88.4 billion profit in H1 2025.

Nigerian Breweries Plc has delivered a remarkable turnaround in H1 2025, swinging from a ₦85.2 billion loss in H1 2024 to an ₦88.4 billion profit. This performance reflects a combination of strong revenue growth, disciplined cost management, and sharply lower finance costs, positioning the company for a more stable and profitable future despite lingering macroeconomic pressures.

Duopharma Biotech Bhd (KLSE: DPHARMA, ticker 7148) Healthcare – Pharmaceuticals / Biotech Investment Review Recommendation: HOLD (Initiated) Key Metrics Company Overview Duopharma Biotech Bhd is a leading pharmaceutical manufacturer in Malaysia, involved in the research, development, manufacturing, and distribution of generic and specialty pharmaceutical products. Its operations span: Ethical Classic : General therapeutic generics (e.g., cardiovascular, anti-infectives) Ethical Specialty : Bio-similars for oncology, renal, and metabolic diseases Consumer Healthcare (CHC) : Notable OTC brands like Champs, Flavettes, and Uphamol As of 2025, it exports to multiple countries and operates from 3 GMP-certified manufacturing facilities.

Q2 2025 Financial & Operational Highlights Financial Performance Cash from operating activities: $2.37B (up from $1.31B in Q1; down from $2.81B in Q2 2024) Adjusted funds flow (AFF): $1.52B (down from $2.21B in Q1; down from $2.36B in Q2 2024) Free funds flow (FFF): $355M (down from $983M in Q1; down from $1.21B in Q2 2024) Net earnings: $851M ($0.45/share), down slightly from Q1 ($859M) Capital investment: $1.16B (steady YoY) Net debt: $4.93B (down from $5.08B in Q1) Return to shareholders: $819M $301M share buybacks $368M dividends $150M preferred share redemption Revenue & Margins Total revenue: $12.3B (down from $13.3B in Q1) Operating margin: $2.1B (down from $2.8B in Q1) Upstream margin: $2.1B (down from $3.0B in Q1) Downstream margin shortfall: ($71M) (improved from Q1 shortfall of $237M) Production & Throughput Upstream production: 765,900 BOE/d (down from 818,900 in Q1) Christina Lake: 217,900 bbls/d (↓ wildfire disruption) Foster Creek: 186,100 bbls/d (↓ planned maintenance) Sunrise: 50,300 bbls/d (↓ maintenance) Lloydminster thermal: 97,800 bbls/d (↓ outage at Rush Lake) Downstream crude throughput: 665,800 bbls/d (steady; utilization 92% ) Canadian refining: 112,400 bbls/d (104% utilization) U.S. refining: 553,400 bbls/d (90% utilization) Key Growth & Project Updates Narrows Lake: Achieved first oil (July), ramping to 20–30K bbls/d by year-end. Foster Creek optimization: 87% complete; 4 new boilers adding 80K bbls/d steam capacity.

GSL has delivered strong H1 2025 financial results, underpinned by robust topline growth (+9.7% in Q2, +8% in H1), consistently high fleet utilization (~95–97%), and forward contracted revenue coverage of 96% for 2025 and 80% for 2026. The company maintains a fortress balance sheet, with net leverage below 1×, investment-grade credit ratings, and disciplined capital allocation through dividends and opportunistic buybacks.

Key Highlights Financial Performance (Q3 FY25) Record Revenue : $148.1 million Record Adjusted EBITDA : $83.3 million Record EBITDA : $82.7 million Profit After Tax : $24.2 million Avg. Operating Hashrate : 29.4 EH/s Strong Margins : All-in cash cost per BTC mined at $41k vs.